Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sha Fu

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
NPJ Precision Oncology|September 11, 2023
Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacyAnlin Li, Linfeng Luo, Wei Du, et al.
Cancer Research|September 28, 2023
FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and ActivationYi Ouyang, Ziwei Ou, Wenlong Zhong, et al.
BMC Endocrine Disorders|May 11, 2024
Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinomaYongsheng Huang, Peiliang Lin, Jianwei Liao, et al.
Frontiers in Immunology|June 14, 2023
Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancerYixing Wang, Sha Fu, Xuanye Zhang, et al.
Medical Oncology (Northwood, London, England)|December 17, 2013
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistanceZe-Rui Zhao, Jin-Feng Wang, Yong-Bin Lin, et al.
Journal of Translational Medicine|April 6, 2013
High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFRFang Wang, Sha Fu, Qiong Shao, et al.
Experimental Biology and Medicine (Maywood, N.J.)|May 10, 2014
MicroRNA-30a promotes invasiveness and metastasis in vitro and in vivo through epithelial-mesenchymal transition and results in poor survival of nasopharyngeal carcinoma patientsHai-Yun Wang, Yang-Yang Li, Sha Fu, et al.
Annals of Surgical Oncology|March 31, 2023
Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort StudyLibo Yang, Yuqiong Liu, DanDan Han, et al.
Frontiers in Immunology|February 15, 2018
TGF-β-Induced CD8<sup>+</sup>CD103<sup>+</sup> Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B CellsHaowen Zhong, Ya Liu, Zhenjian Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2023
STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8<sup>+</sup> T-Cell Dysfunction in NSCLCAnlin Li, Yuanyuan Wang, Zhixin Yu, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
NPJ Precision Oncology|September 11, 2023
Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacyAnlin Li, Linfeng Luo, Wei Du, et al.
Cancer Research|September 28, 2023
FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and ActivationYi Ouyang, Ziwei Ou, Wenlong Zhong, et al.
BMC Endocrine Disorders|May 11, 2024
Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinomaYongsheng Huang, Peiliang Lin, Jianwei Liao, et al.
Frontiers in Immunology|June 14, 2023
Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancerYixing Wang, Sha Fu, Xuanye Zhang, et al.
Medical Oncology (Northwood, London, England)|December 17, 2013
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistanceZe-Rui Zhao, Jin-Feng Wang, Yong-Bin Lin, et al.
Journal of Translational Medicine|April 6, 2013
High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFRFang Wang, Sha Fu, Qiong Shao, et al.
Experimental Biology and Medicine (Maywood, N.J.)|May 10, 2014
MicroRNA-30a promotes invasiveness and metastasis in vitro and in vivo through epithelial-mesenchymal transition and results in poor survival of nasopharyngeal carcinoma patientsHai-Yun Wang, Yang-Yang Li, Sha Fu, et al.
Annals of Surgical Oncology|March 31, 2023
Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort StudyLibo Yang, Yuqiong Liu, DanDan Han, et al.
Frontiers in Immunology|February 15, 2018
TGF-β-Induced CD8<sup>+</sup>CD103<sup>+</sup> Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B CellsHaowen Zhong, Ya Liu, Zhenjian Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2023
STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8<sup>+</sup> T-Cell Dysfunction in NSCLCAnlin Li, Yuanyuan Wang, Zhixin Yu, et al.
Pageof 10